Skip to main content
. Author manuscript; available in PMC: 2014 May 22.
Published in final edited form as: Clin Cancer Res. 2007 Jan 15;13(2 0 1):566–575. doi: 10.1158/1078-0432.CCR-06-1576

Fig. 2.

Fig. 2

Cytotoxicity assays done with HLA-A2–restricted CTL or TIL effectors and peptide-loaded T2 cells or glioma target cells. CTL (top and middle rows) were directed against Mart-1, GP100, EphA2, and Her/neu peptides and incubated with peptide-loaded T2 target cells (top row) or glioma target cells (middle row). TIL (bottom row) were incubated with either peptide-loaded T2 cells or the glioma target cells. The effector TIL 1374 cells are specific for tyrosinase (366-377; left) and TIL 771 cells are specific for GP100 (154-162; right) and incubated with the target glioma cells. The phenotypes of the glioma cells used are, for SNB19: HLA-A2+, Mart-1+, GP100+, EphA2+, Her2/neu+; U-251: HLA-A2+, Mart-1+, GP100+, EphA2+, Her2/neu+, tyro+; U-373: HLA-A2+, Mart-1+, GP100+, EphA2+, Her2/neu+, tyro−; A172:HLA-A2−, Mart-1+, GP100+, EphA2+;T98G: HLA-A2+, tyro+; LN229: HLA-A2−, tyro+.